HK1236192A1 - Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them - Google Patents

Description

Coform salts of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester and methods of making the same

Technical Field

The present application relates to co-former (coformer) salts of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate and additionally optionally in the form of a hydrate, including crystalline forms; and methods of making (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester co-former salts.

Background

The compound (8S,9R) -5-fluoro-8- (4-fluorophenyl) -9- (1-methyl-1H-1, 2, 4-triazol-5-yl) -8, 9-dihydro-2H-pyrido [4,3,2-de ] phthalazin-3 (7H) -one tosylate (Compound (A))

Is an inhibitor of poly (ADP-ribose) polymerase (PARP). The preparation methods thereof are described in WO2010017055, WO2011097602 and WO 2012054698. However, the disclosed synthetic route requires chiral chromatography on one of the synthetic intermediates 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (intermediate (A)) in the route for preparing compound (A),

thus, chirally pure (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (Compound (1))

The use of conventional chiral chromatography typically requires more solvent and time. The use of more efficient chromatographic methods such as Simulated Moving Bed (SMB) chromatography still requires the use of expensive chiral chromatographic resins and is not feasible for large scale purification of pharmaceutical compounds. Furthermore, keeping compound (1) in solution for a long time during chromatography leads to epimerization in position 9 of compound (1) and cleavage of the methyl ester group. It is desirable and overcomes these problems to purify compound (1) by replacing the chromatography step with one or more crystallization steps. It is therefore desirable to find an alternative to the use of chiral chromatographic separation to obtain enantiomeric compound (1).

Co-former salts of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate and methods for their preparation are disclosed which address the difficulties.

Embodiments described herein can significantly improve the purity of the desired compound, and can confer additional advantages in the preparation of compound (a) in achieving regulatory approval and sale. The embodiments described herein allow for more consistent production of compounds that meet regulatory standards and guidelines for the purity of approved drugs. A significant reduction in manufacturing time and expense can also be achieved. A significant reduction in the "cis/trans" isomeric impurities of compound (1) can be achieved (where the cis isomer is the (2R,3S) and (2S,3R) forms and the trans isomer is the (2R,3R) form). A higher degree of enantioselectivity of compound (1) can be achieved.

Drawings

Figure 1 depicts the XRPD of compound (1a) of step 1a of examples 1 and 3 obtained using XRPD procedure 2.

Figures 2a and 2b depict chiral HPLC of the compound (1a) of step 1a in example 3.

FIG. 3 depicts the preparation of compound (1a) of step 1a in example 3¹H NMR。

FIG. 4 depicts the TGA/DSC of compound (1a) of step 1a in example 3.

Figure 5 depicts the XRPD of compound (1a) (above) from example 1 and compound (1a) from example 1, obtained using XRPD procedure 2.

FIG. 6 depicts chiral HPLC of compound (1a) of step 1b in example 3.

Figure 7 depicts the XRPD of compound (1) and intermediate (a) of step 2 in example 3.

FIG. 8 depicts the compound (1) and intermediates (A) of example 3¹H NMR。

Figure 9 depicts the XRPD of compound (1b) from example 5, compound (1b) from example 1 and intermediate (a) obtained using XRPD procedure 2.

FIG. 10 depicts chiral HPLC of compound (1b) in example 5.

FIG. 11 depicts the preparation of Compound (1b) in example 5¹H NMR。

FIG. 12a depicts the TGA and DSC of compound (1b) of example 5.

Figure 12b depicts DSC of compound (1b) in example 5 (below) and compound (1b) in example 1.

FIG. 13a depicts the compound (1a) of example 4¹H NMR (in DMSO-d)₆In (1).

FIG. 13b depicts the compound (1a) of example 4¹³C NMR (in DMSO-d)₆In (1).

FIG. 14 depicts the IR spectrum of compound (1a) in example 4.

FIG. 15 depicts the DSC of compound (1a) in example 4.

FIG. 16 depicts chiral HPLC of compound (1a) in example 4.

FIG. 17a depicts the compound (1) of example 4¹H NMR (in DMSO-d)₆In (1).

FIG. 17b depicts the compound (1) of example 4¹³C NMR (in DMSO-d)₆In (1).

FIG. 18 depicts the IR spectrum of compound (1) in example 4.

FIG. 19 depicts DSC of compound (1) in example 4.

FIG. 20 depicts chiral HPLC of compound (1) in example 4.

Disclosure of Invention

In one aspect, the present application provides co-adult salts of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate thereof.

In certain embodiments, the co-former salt is in a substantially pure crystalline form.

In certain embodiments, the coformer salt is the [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.

In certain embodiments, the coformidic acid is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid.

In certain embodiments, the co-former salt is in a crystalline form exhibiting at least one of: solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum; a differential scanning calorimetry thermogram having a broad endotherm between 25 ℃ and 90 ℃ and an endotherm with a maximum between about 135 ℃ and 147 ℃; thermogravimetric thermograms indicated as solvated species; or an X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5, and 22.

In some embodiments, the co-former salt is in a crystalline form exhibiting at least one of: solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum; or an X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5, and 22.

In some embodiments, the coformer salt is (S) -1-phenylethanesulfonate salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.

In some embodiments, the coformidic acid is (1S) -phenylethanesulfonate.

In another aspect, the present application provides a process for preparing a co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate comprising (1) treating methyl 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate with a co-former in one or more of the step 1a) solvents selected from MIBK, MEK, ethanol and water at elevated temperature, forming a solution of step 1 a); (2) allowing the step 1a) solution to stand under conditions sufficient to precipitate the coformer salt in crystalline form; and (3) isolating the co-former salt in crystalline form.

In certain embodiments, the coformer salt is the [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate salt of compound (1), and the step 1a) solvent is selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone (MIBK), methanol, ethanol, propanol, isopropanol, and butanol.

In certain embodiments, the coformer salt is the [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid salt of compound (1), and the step 1a) solvent is MIBK, water, and ethanol.

In certain embodiments, the co-former salt is the [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate salt of compound (1), and the step 1a) solvent is MIBK and ethanol.

In certain embodiments, the method further comprises recrystallizing or reslurrying the coformer salt in one or more of the step 1b) solvents.

In certain embodiments, the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate is in a crystalline form after recrystallization or reslurry in the solvent of step 1 b).

In certain embodiments, the method further comprises suspending the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate in one or more of the step 2a) solvents selected from water, acetone, IPA, or methanol at room or elevated temperature to form a step 2a) solution, and adding a solvent selected from NaOH, NH, or methanol to the solution to form a solution₃(optional 25% NH)₃Aqueous solution), NaCO₃NaOAc or NaHCO₃Treating the step 2a) solution with a base; allowing the solution of step 2a) to stand under conditions sufficient to precipitate a crystalline form of the methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate; and isolating a crystalline form of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester.

In certain embodiments, the step 2a) solvent is selected from acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol or isopropanol; and the base is NH₃An aqueous solution.

In certain embodiments, the step 2a) solvents are acetone, methanol, and 2-propanol; and the base is NH₃An aqueous solution.

In certain embodiments, the step 2a) solvents are acetone, methanol, and isopropanol; and the base is NH₃An aqueous solution.

In certain embodiments, the method further comprises recrystallizing or reslurrying (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester in one or more of the step 2b) solvents.

In certain embodiments, the (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester is in crystalline form after recrystallization or reslurry in step 2b) solvent (S).

In another aspect, the present application provides the compound (2S,3S) -methyl 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate and additionally optionally in the form of a hydrate, prepared by: treating the co-former salt of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester with a base and isolating the methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.

Detailed Description

Abbreviations

Abbreviations	Means of
		ACN	Acetonitrile
DCM	Methylene dichloride
		DMF	N, N-dimethylformamide
DSC	Differential scanning calorimetry
		EA	Ethyl acetate
e.e.	EnantiomersExcess of
		EtOH	Ethanol
equiv	Equivalent weight
		g	Keke (Chinese character of 'Keke')
IPA	Isopropanol (I-propanol)
		IR	Infrared ray
mHz	Megahertz
		MEK	Methyl ethyl ketone
MIBK	Methyl isobutyl ketone
		mL	Milliliter (ml)
mol	Mole of
		NaOH	Sodium hydroxide
NMR	Nuclear magnetic resonance
		TGA	Thermogravimetric analysis
THF	Tetrahydrofuran (THF)
		XRPD	Powder X-ray diffraction

Definition of

To facilitate understanding of the invention described herein, a number of terms are defined below. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Where there are multiple definitions of terms used in this application, those in this section prevail unless otherwise stated.

As used throughout this application and the appended claims, the following terms have the following meanings:

as used in this application, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a compound" includes mixtures of two or more compounds, and the like.

As used herein, and unless otherwise specified, the terms "about" and "approximately" when used in conjunction with a dose, amount, or weight percentage of an ingredient of a composition or dosage form, means the dose, amount, or weight percentage recognized by one of ordinary skill in the art to provide an equivalent pharmacological effect obtained from the specified dose, amount, or weight percentage. In certain embodiments, the terms "about" and "approximately" as used in this context encompass a dose, amount, or weight percent that is within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the specified dose, amount, or weight percent.

As used herein, and unless otherwise specified, the terms "about" and "approximately" are to be construed as providing a value or range of values for describing a particular solid form (e.g., a particular temperature or range of temperatures, such as describing a melting, dehydrating, desolvating, or glass transition; a change in mass, such as a change in mass as a function of temperature or humidity; solvent or water content, expressed in mass or percentage, for example; or peak position, such as at¹³C NMR, DSC, TGA, and XRPD analysis), indicates that the value or range of values may deviate to the extent that one of ordinary skill in the art would deem it reasonable but still describe a particular solid form. In certain embodiments, the terms "about" and "approximately" when used in this context indicate that a value or range of values can vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the value or range of values but still describe a particular solid form.

The term "amorphous" or "amorphous form" means that the substance, component or product is not substantially crystalline, as determined, for example, by XRPD, or, when viewed microscopically, is not birefringent, for example. In certain embodiments, a sample comprising an amorphous form of a substance may be substantially free of other amorphous and/or crystalline forms.

The term "crystalline form" or "crystalline form" refers to a crystalline solid form of a compound, including, but not limited to, single component or multiple component crystalline forms (e.g., polymorphs of a compound); or a solvate, hydrate, clathrate (clathrate), co-crystal, salt of a compound, or polymorph thereof. The term "crystalline form" and related terms refer herein to various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, co-crystals and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and polymorphs thereof. Crystalline forms of the material may be obtained by a variety of methods as are known in the art. The methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces (such as in nanopores or capillaries), recrystallization on surfaces or templates (such as on polymers), recrystallization in the presence of additives (such as eutectic counter molecules), desolvation, dehydration, fast evaporation, fast cooling, slow cooling, gas phase diffusion, sublimation, milling, and solvent drop milling.

Techniques for characterizing crystalline and amorphous forms include, but are not limited to, TGA, DSC, XRPD, single crystal X-ray diffraction, vibrational spectroscopy (e.g., IR and raman spectroscopy), solid state NMR, optical microscopy, hot stage optical microscopy, SEM, electronic crystallization and quantitation, PSA, surface area analysis, solubility (solubility) studies, and dissolution (dissolution) studies.

As used herein and unless otherwise indicated, the term "hydrate" means a compound or salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.

As used herein and unless otherwise indicated, the term "solvate" means a solvate formed from the association of one or more solvent molecules with a compound provided herein or a salt thereof. The term "solvate" includes hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).

The term "polymorph" or "polymorphic form" means one of two or more crystal forms comprising the same molecule or ions. Different polymorphs can have different physical properties, such as melting temperature, heat of solution, solubility, dissolution rate, and/or vibrational spectra, due to the different arrangement or conformation of molecules or ions in the crystal lattice. The differences in physical properties exhibited by polymorphs can affect the following pharmaceutical parameters: such as storage stability, compressibility, density (important in formulation and product manufacture) and dissolution rate (an important factor in bioavailability). Differences in stability can be caused by changes in chemical reactivity (e.g., differential oxidation, such that a dosage form containing one polymorph discolors faster than a dosage form containing another polymorph), mechanical changes (e.g., tablets crumble upon storage due to a kinetically favored polymorph transforming into a thermodynamically more stable polymorph), or both (e.g., tablets of one polymorph are more prone to breakage at high humidity). Due to solubility/dissolution differences, in extreme cases, some polymorphic transformations may lead to lack of efficacy, or in other extreme cases to toxicity. In addition, the physical properties of the crystalline form may be critical in processing; for example, one polymorph may be more likely to form solvates, or may be difficult to filter and wash away impurities (e.g., particle shape and size distribution may differ between polymorphs).

As used herein, "substantially pure" means that a substance or mixture is substantially free of other compounds, stereoisomers, co-former salts, solvates, hydrates, or other solid forms thereof, including other crystalline or amorphous forms. In certain instances, a "substantially pure" compound, such as substantially pure methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate or a co-former salt or solvate thereof, may refer to being substantially free of other compounds, such as unreacted precursors and by-products that may be present in a process for preparing a desired compound. In other instances, a "substantially pure" solid form (e.g., crystalline or amorphous form) of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, or a salt or solvate thereof, as used herein, may refer to other solid forms that are substantially free of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, or a salt or solvate thereof. In certain instances, "stereomerically pure" means that a composition comprises one stereoisomer of a compound and is substantially free of other stereoisomers of the compound.

The term "volume (vol)" as used herein refers to the weight/volume ratio of solid reactant to liquid solvent. For example, 250g of solid material in 10 volumes of solvent means that the material is dissolved in 10 x 250mL or 2.5L of solvent.

It is understood that the co-former salt of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester comprises a cation of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (e.g., in one embodiment, protonated at one atomic position, or in other embodiments, protonated at more than one atom position) and the anion of the co-former acid.

Detailed description of the preferred embodiments

The following paragraphs set forth various embodiments of the compounds and methods disclosed herein and are not intended to be limiting.

In one aspect, the present invention provides a co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (hereinafter referred to as "co-former salt of compound (1)), optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate thereof. In certain embodiments, the co-former salt comprises an anion of a chiral acid. In certain embodiments, the chiral acid is selected from table 1. In certain embodiments, the chiral acid is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid or (1S) -phenylethanesulfonic acid. In certain embodiments, the co-former salt is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (hereinafter the co-former salt is referred to as "compound (1 a)"), optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate thereof. In certain embodiments, the co-former salt is the (S) -1-phenylethanesulfonate salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (hereinafter the co-former salt is referred to as "compound (1 b)"), optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate thereof. In certain embodiments, the co-former salt of compound (1) and compounds (1a) and (1b) comprise a molar ratio of cation to anion of about 1:1. In certain embodiments, the molar ratio of cation to anion is about 1:1.1, about 1:1.15, about 1:1.2, or about 1: 1.3.

In certain embodiments, the co-former salt of compound (1) and compounds (1a) and (1b) are unsolvated.

In certain embodiments, the co-former salt of compound (1) and compounds (1a) and (1b) are solvates thereof. In certain embodiments, the solvated form is a hydrate thereof. In certain embodiments, the solvate form is an ethanolate solvate thereof. In certain embodiments, the solvate forms are ethanolate solvates and hydrates thereof. In certain embodiments, the ratio of the co-former salt of compound (1) or compound (1a) or compound (1b) to ethanol solvate is about 1:0.4, about 1:0.5, about 1:0.6, or about 1: 0.7. In certain embodiments, the ratio of the co-former salt of compound (1) or compound (1a) or compound (1b) to the hydrate is about 1:0.4, about 1:0.5, about 1:0.6, or about 1: 0.7.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are in solid form. In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are amorphous. In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are in crystalline form, amorphous form, or mixtures thereof. In certain embodiments, the co-former salt of compound (1) and the ethanolate solvates, hydrates, or mixtures thereof of compounds (1a) and (1b) are in crystalline form, amorphous form, or mixtures thereof.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are in amorphous form. In certain embodiments, the co-former salt of compound (1) and the ethanolate solvates, hydrates, or mixtures thereof of compounds (1a) and (1b) are in amorphous form.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are in crystalline form. In certain embodiments, the co-former salt of compound (1) and the ethanolate solvates, hydrates, or mixtures thereof of compounds (1a) and (1b) are in crystalline form.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are substantially pure. In certain embodiments, the co-former salts of compound (1) and the solid or crystalline forms of compounds (1a) and (1b) and solvates and hydrates thereof are substantially pure. In certain embodiments, the co-former salts of compound (1) and the crystalline forms of compounds (1a) and (1b) and solvates and hydrates thereof are substantially pure. In certain embodiments, the co-former salt of compound (1) and the ethanolate solvates, hydrates, or mixtures thereof of compounds (1a) and (1b) are substantially pure.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are stereochemically pure. In certain embodiments, the co-former salts of compound (1) and the solid or crystalline forms of compounds (1a) and (1b) and solvates and hydrates thereof are stereochemically pure. In certain embodiments, the co-former salts of compound (1) and the crystalline forms of compounds (1a) and (1b) and solvates and hydrates thereof are stereochemically pure. In certain embodiments, the co-former salts of compound (1) and the ethanolate solvates, hydrates, or mixtures thereof of compounds (1a) and (1b) are stereochemically pure.

In certain embodiments, the substantially pure co-former salt comprises substantially pure methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, substantially free of other stereoisomers including, for example, methyl (2R,3R) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl), (2S,3R) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester and (2R,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester. In certain embodiments, the co-former salt of compound (1) and compounds (1a) and (1b) comprise about 100% by weight of compound (1) of a particular stereoisomer, wherein the percentages are based on the total amount of the combined stereoisomers in the stereochemically pure co-former salt.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof comprise greater than about 80% by weight of compound (1) and less than about 20% by weight of any stereoisomer of compound (1), greater than about 90% by weight of compound (1) and less than about 10% by weight of any stereoisomer of compound (1), greater than about 95% by weight of compound (1) and less than about 5% by weight of any stereoisomer of compound (1), greater than about 97% by weight of compound (1) and less than about 3% by weight of any stereoisomer of compound (1), greater than about 99% by weight of compound (1) and less than about 1% by weight of any stereoisomer of compound (1), or greater than about 99.5% by weight of compound (1) and less than about 0.5% by weight of any stereoisomer of compound (1). The above percentages are based on the total amount of stereoisomers combined in the stereochemically pure co-former salt.

In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are substantially free of one or more other specific crystalline forms, amorphous forms, and/or other compounds. In certain embodiments, the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof comprise less than about 10 wt%, less than about 5 wt%, less than about 3 wt%, less than about 2 wt%, less than about 1 wt%, less than about 0.75 wt%, less than about 0.5 wt%, less than about 0.25 wt%, or less than about 0.1 wt% of one or more other crystalline or amorphous forms of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate and/or other compounds that may result from the synthetic methods disclosed herein. In certain embodiments, the co-former salt of compound (1) and the crystalline forms of compounds (1a) and (1b) are substantially free of amorphous forms.

In certain embodiments, the co-former salt of compound (1) and the crystalline salts of compounds (1a) and (1b) and solvates and hydrates thereof are at least about 90 wt%, at least about 95 wt%, at least about 97 wt%, at least about 98 wt%, at least about 99 wt%, at least about 99.2 wt%, at least about 99.5 wt%, at least about 99.6 wt%, at least about 99.7 wt%, or at least about 99.8 wt% pure in a single crystalline form, the remainder of the total weight can be other crystalline or amorphous forms and/or other compounds.

In certain embodiments, the co-former salts of compound (1) and the crystalline forms of compounds (1a) and (1b) and solvates and hydrates thereof are substantially single component crystalline forms or single polymorphs. In certain embodiments, the crystalline forms of the co-former salts of compound (1) and compounds (1a) and (1b) and solvates and hydrates thereof are multicomponent crystalline forms comprising a first crystalline form of these co-former salts and at least one other crystalline and/or amorphous form of these co-former salts.

In certain embodiments, the coformer salt is a crystalline compound (1a) having an XRPD pattern comprising one or more (e.g., 1,2,3,4, 5, 6, 7, 8,9, 10, or greater than 10; or at least 3, at least 4, at least 5, at least 6, or at least 7) characteristic peaks selected from peaks having an angle 2 Θ according to fig. 1 or fig. 5. In certain embodiments, the XRPD pattern of the crystalline compound (1a) comprises one or more (e.g., 1,2,3,4, 5 or at least 2, at least 3, or at least 4) characteristic peaks selected from peaks having 2 Θ angles of about 6.7, 9.7, 18.5, 19.5, and 22 ± 0.22 Θ. In certain embodiments, the XRPD pattern of the crystalline compound (1a) comprises characteristic peaks selected from peaks having 2 Θ angles ± 0.22 Θ of about 6.7 and 9.7. In certain embodiments, the XRPD pattern of the crystalline compound (1a) is substantially as provided in figure 1 or figure 5.

In certain embodiments, the co-former salt is a salt having a spectrum substantially corresponding to that in fig. 13b¹³A C NMR spectrum or a spectrum of peaks substantially corresponding to those in table a, wherein an entry having 2 peaks represents a doublet:

TABLE A

In certain embodiments, the crystalline compound (1a) is¹³The C NMR spectrum comprises one or more peaks (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 peaks) selected from peaks at about 210.3, 58.1, 56.0, 54.7, 48.6, 47.0, 46.3, 40.6, 25.3, 21.8, 20.8, 19.5, and 18.5 about ± 0.2 ppm. In certain embodiments, the crystalline compound (1a)¹³The CNMR spectrum comprises one or more peaks (e.g., at least 2, at least 3, at least 4, or at least 5 peaks) at about 210.3, 25.3, 21.8, 20.8, 19.5, and 18.5 about ± 0.2 ppm.

In certain embodiments, the coformer salt is a crystalline compound (1a) having a broad endothermic peak between 25 ℃ and about 90 ℃ and an endotherm with a maximum between about 135 ℃ and 150 ℃, between about 140 ℃ and 150 ℃, or between about 143 ℃ and 147 ℃ based on differential scanning calorimetry analysis. In certain embodiments, crystalline compound (1a) has an endotherm with a maximum between about 135 ℃ and 150 ℃, between about 140 ℃ and 150 ℃, or between about 143 ℃ and 147 ℃.

In certain embodiments, the coformer salt is crystalline compound (1a) having a DSC thermogram (thermogram) substantially corresponding to the DSC thermogram (thermogram) of fig. 4 or fig. 15.

In certain embodiments, the co-former salt is crystalline compound (1a) having a TGA thermogram indicated as a solvated species. In certain embodiments, crystalline compound (1a) has a TGA thermogram substantially corresponding to the TGA thermogram of figure 4. In certain embodiments, crystalline compound (1a) has a TGA thermogram that exhibits a gradual weight loss (e.g., between about 2.5% and 4.5%, between about 3% and 4%, about 3.5%) when heated from about 25 ℃ to a temperature of about 90 ℃. In certain embodiments, crystalline compound (1a) has a TGA thermogram that exhibits a gradual weight loss (e.g., between about 0.5% and 2%, between about 0.75% and 1.75%, between about 1% and 1.5%, about 1.2%) when heated from about 90 ℃ to a temperature of about 160 ℃.

In certain embodiments, the co-former salt is a crystalline compound (1a) having at least one of: i. solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum; a differential scanning calorimetry thermogram having a broad endotherm between 25 ℃ and 90 ℃ and an endotherm with a maximum between about 135 ℃ and 147 ℃; iii. Thermogravimetric thermograms indicated as solvated species; an X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5, and 22. In certain embodiments, the crystalline compound (1a) has at least one of: i. solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum; an X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5 and 22.

In certain embodiments, the coformer salt is (S) -1-phenylethanesulfonate salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (compound (1 b)).

In another aspect, the invention provides substantially pure methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (compound (1)) prepared by: treating the co-former salt of compound (1) with a base and isolating (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (compound (1)). In certain embodiments, the isolated compound (1) is optionally recrystallized.

Process for preparing compounds

The present application provides methods of preparing compound (1) and its co-former salts.

In certain embodiments, the methods can provide, for example, improved product recovery, product purity, and/or compliance for large-scale production, as compared to previously reported syntheses of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester.

In certain embodiments, the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate, is prepared in crystalline form, yielding compound (1) having a higher purity as compared to compound (1) isolated by chiral chromatography.

In certain embodiments, the preparation of compound (1) using a co-former is more amenable to large scale production than preparation using chiral chromatography.

Scheme a provides an exemplary illustration of a method for preparing the co-former salt of compound (1).

Scheme A

In step 1a), the intermediate (a) may be dissolved at room temperature or at elevated temperature (temperature above room temperature) in one or more of the solvents of step 1a), wherein the solvent is sufficient to dissolve the intermediate (a). In certain embodiments, the elevated temperature is about 30 ℃, about 35 ℃, about 40 ℃, about 45 ℃, about 48 ℃, about 50 ℃, about 52 ℃, about 55 ℃, about 60 ℃, about 65 ℃, or about 70 ℃. In certain embodiments, the step 1a) solvent is C_1-6Ketones, C_1-6Alcohol, ethyl acetate ("EA"), tetrahydrofuran ("THF"), toluene, acetonitrile ("ACN"), heptane, dioxane, or water; or a combination thereof. In certain embodiments, said C_1-6The ketone is acetone, methyl ethyl ketone ("MEK") or methyl isobutyl ketone ("MIBK"). In certain embodiments, said C_1-6The alcohol is methanol, ethanol, propanol, isopropanol or butanol. In certain embodiments, said C_1-6The alcohol is methanol, ethanol or isopropanol. In certain embodiments, the step 1a) solvents are ethanol and MIBK; or the solvent is ethanol, MIBK and water.

In certain embodiments, the MIBK/ethanol ratio is from 5 to 20/1; or the ratio is 5/1 or 6/1 or 7/1 or 8/1 or 9/1 or 10/1 or 11/1 or 12/1 or 15/1 or 20/1. In certain embodiments, the MIBK/ethanol ratio is 9: 1.

In certain embodiments, the MIBK/ethanol/water ratio is from 10 to 15/1 to 1.5/0.1 to 0.05; or the ratio is 12-13/1-1.5/0.1-0.05. In certain embodiments, the MIBK/ethanol/water ratio is 13/1.5/0.1; or 13/1.5/0.05; or 13/1/0.1; or 13/1/0.05; or 12/1.5/0.1; or 12/1.5/0.05; or 12/1/0.1; or 12/1/0.05.

In certain embodiments, in step 1a), the intermediate (a) may be dissolved at an elevated temperature (e.g., at about 30 ℃, about 35 ℃, about 40 ℃, about 45 ℃, about 48 ℃, about 50 ℃, about 52 ℃, about 55 ℃, about 60 ℃, about 65 ℃, or about 70 ℃) in one or more step 1a) solvents such as acetone, IPA, EA, THF, DMF, toluene, ACN, heptane, dioxane, water, MIBK, MEK, or ethanol, or a combination thereof, to form a step 1a) solution.

In certain embodiments, the step 1a) solvent is MIBK, MEK, water and/or ethanol. In certain embodiments, the ratio of MIBK: MEK: ethanol/water is 20-40:10-20: 1-10. In certain embodiments, the ratio of MIBK: MEK: ethanol/water is from 10-30:20 to 30: 1-5.

In certain embodiments, the step 1a) solvent is MIBK, water and/or ethanol. In certain embodiments, the step 1a) solvent is MIBK: ethanol: water in a ratio of 30-50:5-10:1-5 or 35-45:6-7:1-2 or 40:6.5: 1.6. In certain embodiments, the MIBK: ethanol: water ratio is from 130:10 to 15:0.5 to 1, 120-. In certain embodiments, the step 1a) solvent is MIBK: ethanol in a ratio of 5-20:1 or 10-20:1 or 19:1 or 18:1 or 10:1 or 9:1 or 8: 1.

In certain embodiments, the step 1a) solvents are ethanol and MEK. In certain embodiments, the ratio of ethanol to MEK is from 85 to 99:1 to 15, or from 90 to 99:1 to 10, or from 95 to 99:1 to 5, or from 95:5, or from 96:4, or from 97:3, or from 98: 2.

In certain embodiments, the intermediate (a) is dissolved in about 5 volumes of one or more step 1a) solvents, about 7 volumes of one or more step 1a) solvents, about 10 volumes of one or more step 1a) solvents, about 12 volumes of one or more step 1a) solvents, about 14 volumes of one or more step 1a) solvents, about 16 volumes of one or more step 1a) solvents, or about 20 volumes of one or more step 1a) solvents.

A co-former acid (about 1 molar equivalent) may be added and dissolved in the step 1a) solution to prepare the step 1a) co-former solution. A solid form of the co-former salt of compound (1) may be obtained by: seeding the step 1a) coformer solution with a crystal of a coformer salt of compound (1), or cooling the step 1a) coformer solution to about room temperature, about 20 ℃, about 15 ℃, about 10 ℃, about 5 ℃, about 0 ℃, about-5 ℃, about-10 ℃, or about-15 ℃. Once the co-former salt of solid compound (1) is formed, it can be collected by filtration, optionally washed with step 1a) solvent, and dried.

In step 1b), the co-former salt of compound (1) may be resuspended in the step 1b) solvent to form a step 1b) solution. In certain embodiments, the step 1b) solvent is the same solvent as the one or more step 1a) solvents.

In certain embodiments, the coformer salt of compound (1) is resuspended at an elevated temperature (e.g., at about 30 ℃, about 35 ℃, about 40 ℃, about 45 ℃, about 50 ℃, about 55 ℃, about 60 ℃, about 65 ℃, about 70 ℃) in about 5 volumes of one or more step 1a) solvents, about 7 volumes of one or more step 1a) solvents, about 10 volumes of one or more step 1a) solvents, about 12 volumes of one or more step 1a) solvents, about 14 volumes of one or more step 1a) solvents, about 16 volumes of one or more step 1a) solvents, or about 20 volumes of one or more step 1a) solvents to form a step 1b) solution. The step 1b) solution may optionally be cooled to about room temperature, about 20 ℃, about 15 ℃, about 10 ℃, about 5 ℃, about 0 ℃, about-5 ℃, about-10 ℃, or about-15 ℃ to prepare a solid form of the co-former salt of compound (1). The solid coformer salt may be collected by filtration, optionally washed with the step 1b) solvent, and dried.

In step 2a), a base may be added to the co-former salt solution of compound (1)To release compound (1) and remove the corresponding co-forming acid. Any base sufficient to release compound (1) may be used. In certain embodiments, the base is aqueous ammonia (e.g., NH)₄OH)、NaOH、NaOAc、NaHCO₃Or Na₂CO₃. In certain embodiments, the base is aqueous ammonia (e.g., NH)₄OH). In certain embodiments, the base is NaOH.

In certain embodiments, the step 2a) solvent can be any solvent or combination of solvents sufficient to dissolve the co-former salt of compound (1) or can form a suspension sufficient to allow a suitable base to react to release compound (1). In certain embodiments, the step 2a) solvent may be any step 1a) solvent. In certain embodiments, the step 2a) solvent may be C_1-6Ketones, C_1-6Alcohol or water; or a combination thereof. In certain embodiments, said C_1-6The ketone is acetone, MIBK or MEK. In certain embodiments, said C_1-6The ketone is acetone. In certain embodiments, said C_1-6The alcohol is methanol, ethanol, 2-propanol or isopropanol. In certain embodiments, said C_1-6The alcohol is methanol, 2-propanol or isopropanol. In certain embodiments, the step 2a) solvent may be acetone, methanol, 2-propanol, isopropanol, or water; or a combination thereof. In certain embodiments, the step 2a) solvent may be acetone and methanol; or they may be acetone, methanol, 2-propanol and water; or they may be acetone, methanol and isopropanol; or they may be acetone, methanol, isopropanol and water.

In step 2a), the catalyst may be prepared by reaction of a catalyst selected from NH₄OH、NaOH、NaOAc、NaHCO₃Or Na₂CO₃Suspending a co-former salt of compound (1) in the presence of a base selected from C_1-6Ketones, C_1-6Alcohol and water, or a combination thereof, in step 2a) solvent to release compound (1). In certain embodiments, the step 2a) solvent is acetone, methanol, 2-propanol, isopropanol, or water, or a combination thereof, and the base is NH₄OH or aqueous NaOH solution. In certain embodiments, the base is NH₄OH。In certain embodiments, the step 2a) solvents are acetone, methanol, and isopropanol, and the base is NH₄And (5) OH. In certain embodiments, the step 2a) solvent is acetone, methanol, isopropanol, and water, and the base is NH₄And (5) OH. In certain embodiments, the step 2a) solvents are acetone, methanol, and 2-propanol, and the base is NH₄OH。

In step 2a), compound (1) may be released by suspending the co-former salt of compound (1) in about 0.5 to about 10 volumes, or about 0.5 to about 5 volumes, or about 0.75 to about 2.5 volumes, of one or more step 2a) solvents at room or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃) to form a step 2a) solution, and treating the step 2a) solution with about 1-1.5 equivalents of an appropriate base. In some embodiments, the coformer salt is suspended in about 0.75 volume or about 1 volume or about 1.5 volume or about 1.7 volume or about 2 volume or about 2.2 volume or about 2.4 volume or about 2.5 volume of one or more of the step 2a) solvents at room or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃) to form a step 2a) solution, and the step 2a) solution is treated with about 1.1 equivalents or about 1.2 equivalents or about 1.3 equivalents or about 1.4 equivalents or about 1.5 equivalents of an appropriate base. In certain embodiments, the coformer salt is suspended in about 0.5 to about 10 volumes or about 0.5 to about 5 volumes or about 0.75 to about 2.5 volumes of one or more step 2a) solvents selected from the group consisting of acetone, methanol, propanol, isopropanol and water at room or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃) to form a step 2a) solution and is treated with about 1-1.5 equivalents of one or more solvents selected from the group consisting of NaOH, NH, and water to form a step 2a) solution₃Aqueous solution (optionally as 25% NH)₃Aqueous solution), NaCO₃NaOAc and NaHCO₃Treating the step 2a) solution with a base. In certain embodiments, the coformer salt is suspended in about 0.75 volume or about 1 volume or about 1.5 volume or about 1.7 volume or about 2 volume or about 2.2 volume at room temperature or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃)By volume or about 2.4 volumes or about 2.5 volumes of one or more step 2a) solvents selected from acetone, methanol, propanol, isopropanol and water to form a step 2a) solution and using about 1 equivalent or about 1.1 equivalent or about 1.2 equivalents or about 1.3 equivalents or about 1.4 equivalents or about 1.5 equivalents of a solvent selected from NaOH, NH₃Aqueous solution (optionally as 25% NH)₃Aqueous solution), NaCO₃NaOAc and NaHCO₃Treating the step 2a) solution with a base.

In certain embodiments, in step 2a), the step 2a) solution may be formed by suspending the co-former salt of compound (1) in about 0.75, about 1, about 1.5, about 1.7, about 2, about 2.2 or about 2.4 volumes of one or more step 2a) solvents such as water, acetone, IPA and methanol at room or elevated temperature (e.g., about 30, about 35, about 37, about 38, about 40, about 42 or about 45 ℃) and using about 1, about 1.1, about 1.2, about 1.3 or about 1.4 equivalents of a solvent such as NaOH, NH, or the like₃(optional 25% NH)₃Aqueous solution), NaCO₃NaOAc or NaHCO₃Treating the solution of step 2a) with a base to release compound (1). The pH can optionally be checked and if the pH is > 7, water (0.55 vol) can be added. The system may be cooled to about 25 ℃, about 30 ℃, about 35 ℃ or about 40 ℃, and optionally seed crystals of compound (1) may be added. Water (3.3 volumes) may be added dropwise over about 30 minutes and the suspension cooled to an internal temperature of about 0 to 5 ℃ over 30 minutes, stirring the reaction mixture over 15 minutes. The solid form of compound (1) can be collected by filtration and washed 3 times with water.

In certain embodiments, the coformer salt is suspended in acetone/isopropanol/methanol at a ratio of about 2-6 volumes/1-2 volumes to form a step 2a) solution at room or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃) and with about 1 equivalent or about 1.1 equivalents or about 1.2 equivalents or about 1.3 equivalents or about 1.4 equivalents or about 1.5 equivalents of NH to form a step 2a) solution₃Aqueous solution (optionally as 25% NH)₃Aqueous solution) treating the step 2a) solution. In certain embodiments, the acetone/isopropyl alcohol isThe alcohol/methanol ratio is about 2-4 vol/1-2 vol or about 2-4 vol/1 vol or about 2 vol/1 vol. In certain embodiments, the coformer salt is suspended in acetone/isopropanol/methanol at a ratio of about 2 volumes/1 volumes to form a step 2a) solution at room or elevated temperature (e.g., about 30 ℃, about 32 ℃, about 35 ℃, about 37 ℃, about 38 ℃, about 40 ℃, about 42 ℃, about 45 ℃) and with about 1.3 equivalents of NH₃Aqueous solution (optionally as 25% NH)₃Aqueous solution) treating the step 2a) solution.

In step 2b), the e.e. of compound (1) may be improved, if desired, in an optional step by using about 4, about 5, about 6 or about 7 volumes of one or more of the step 2b) solvents such as water, acetone, IPA or methanol. For example, acetone (4 vol), IPA (1 vol) and methanol (1 vol) may be added to the product of the previous step 2a) and the reaction mixture may be heated to an internal temperature of about 38 ℃ to 42 ℃, about 35 ℃, about 38 ℃, about 40 ℃, about 42 ℃ or about 45 ℃ to give a clear solution of step 2 b). Water (2 volumes) and seeds of compound (1) may be added to the step 2b) solution and the system stirred at an internal temperature of about 35 ℃ for about 15 minutes. Water may be added dropwise over about 30 minutes. The suspension may then be cooled to an internal temperature of about 0 to 5 ℃ over 30min and stirred for an additional 15 minutes. The solid can be collected by filtration, washed twice with water, and the chiral purity determined. The solid may be dried under reduced pressure at an internal temperature of about 60 ℃ to give compound (1).

In certain embodiments, the methods provide substantially pure compound (1). In certain embodiments, the methods provide compound (1) having 90-99% e.e. or 95% -99% e.e. or 97% -99% e.e. or ≥ 96%, e.e. or ≥ 97% e.e. or ≥ 98% e.e. or ≥ 99% e.e or 99.5% e.e.

In another aspect, the present application provides a method of preparing a co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate (compound (1)) comprising (1) treating 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1 with a co-former in one or more step 1a) solvents selected from MIBK, MEK, ethanol and water at elevated temperature, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester to form the step 1a) solution; (2) allowing the solution of step 1a) to stand under conditions sufficient to precipitate (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (compound (1)) as a solid and in some embodiments as a crystalline form; and (3) isolating compound (1) as a solid and in certain embodiments in crystalline form.

In certain embodiments, the coformer salt is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate and the step 1a) solvent is MIBK, water and ethanol.

In certain embodiments, the method further comprises recrystallizing or reslurrying the coformer salt in one or more of the step 1b) solvents.

In certain embodiments, the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate is in a crystalline form after recrystallization or reslurry of the co-former salt in one or more of the step 1b) solvents.

In certain embodiments, the method further comprises suspending the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate in one or more step 2a) solvents selected from water, acetone, IPA, or methanol at room or elevated temperature to form a step 2a) solution, and adding a solvent selected from NaOH, NH, or methanol to the solution to form a step 2a) solution₃(optional 25% NH)₃Aqueous solution), NaCO₃、NaOAc₃Or NaHCO₃Treating the step 2a) solution with a base; allowing the solution of step 2a) to stand under conditions sufficient to precipitate (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester (compound (1)) as a solid and in some embodiments as a crystalline form; and (3) separation as a solid and in certain embodimentsCompound (1) in crystalline form.

In certain embodiments, the method further comprises recrystallizing or reslurrying compound (1) in one or more of the step 2b) solvents. In certain embodiments, compound (1) is in a crystalline form after recrystallization or reslurry of the coformer salt in the one or more step 2b) solvents.

Preparation of the Compounds

The following are examples that illustrate how the coformer salts of the present invention may be prepared and tested. While the examples merely represent certain embodiments, it is to be understood that the following examples are illustrative and not intended to be limiting.

In certain embodiments, the method of preparing a co-former salt of compound (1) comprises any of the various embodiments described above and below.

The compounds disclosed herein are commercially available or can be readily prepared from commercially available starting materials according to established procedures in the field of organic synthesis. General methods for synthesizing compounds of The invention can be found, for example, in Stuart Warren and Paul Wyatt, Workbook for Organic Synthesis The DisconnectionAproach, second edition, Wiley, 2010. The synthesis of some compounds is exemplified in detail below.

In certain embodiments, individual stereoisomers of the compounds of the present invention are prepared synthetically from commercially available starting materials containing asymmetric or chiral centers or by preparation of racemic mixtures followed by stereoselective separation of the enantiomers. Stereoselective separation methods include, for example, (1) binding the enantiomeric mixture to a chiral auxiliary, separating the resulting diastereomeric mixture by recrystallization or chromatography and liberating the optically pure product from the auxiliary; or (2) directly separating the mixture of optical enantiomers on a chiral chromatography column.

X-ray powder diffraction (XRPD)

Unless otherwise specified, when XRPD peaks are expressed in terms of 2 θ, it is understood that copper ka 1 radiation is used.

In certain embodiments, the 2 θ angular values provided herein vary over a range of about ± 0.2 ° θ, while still describing the same XRPD peaks.

XRPD procedure 1X-ray powder diffraction patterns were collected on a Bruker AXS C2GADDS diffractor using Cu K α radiation (40kV, 40mA), an XYZ automatic stage, a laser video microscope for automatic sample positioning, and a HiStar two-dimensional area detector X-ray optics were made up of a single piece coupled with a 0.3mm pinhole collimatorA multilayer mirror. Weekly efficacy checks were performed using the identified standard NIST 1976 corundum (plate). The beam divergence, i.e. the effective size of the X-ray beam on the sample, is about 4 mm. A continuous scan pattern of Θ - Θ is used, with a sample-detector distance of 20cm, yielding an effective 2 Θ range of 3.2 ° to 29.7 °. The exposure of the sample to the X-ray beam typically lasts 120 seconds. GADDS of XP/20004.1.43 software was used for data collection, and Diffrac Plus EVA v13.0.0.2 or v15.0.0.0 software was used for data analysis and presentation.Environmental strip Piece: samples operating at ambient conditions were prepared as flat plate specimens using as received powder without milling; approximately 1-2mg of the sample was gently pressed on a slide to obtain a flat surface.Non-environmental conditions: samples operating under non-ambient conditions were mounted on a silicon wafer along with a heat transfer compound. The sample was then heated to the appropriate temperature at 10 ℃/min and then held isothermally for 1 minute before data collection was initiated.

XRPD operation 2Optionally, X-ray powder diffraction patterns were collected using Cu K α radiation (40kV, 40mA), theta-2 theta goniometer and V4 on a Bruker D8 diffractor, divergence of the receiving slit, Ge monochromator and Lynxeyer detectorThe device is used for data analysis and presentation. The samples were run at ambient conditions using the as-received powder as a flat plate specimen. The sample was lightly encapsulated in a cavity cut in a polished zero background (510) silicon wafer. During analysis, the sample is rotated in its own plane. The data collection details include: an angular range of 2 to 42 ° 2 Θ, a step size of 0.05 ° 2 Θ, and a collection time of 0.5 s/step.

Single crystal X-ray diffraction (SCXRD)

Data were collected on an Atlas CCD diffractometer equipped with an Oxford diffraction Supernova Dual Source (Cu 0) cooling unit. Data were collected using MoK α radiation. The structure is typically parsed using either the SHELXS or SHELXD program and refined using the SHELXL program, which is part of the Bruker AXS SHELXTL program suite (V6.10). The hydrogen atoms attached to the carbon can be placed geometrically and typically allow refinement with a ring isotropic displacement parameter. The hydrogen atom attached to the heteroatom is located in a difference Fourier (Fourier) synthesis and typically allows free refinement with isotropic shift parameters.

Nuclear magnetic resonance

For examples 1-3 and 5, NMR spectra were collected on a Bruker400MHz instrument equipped with an autosampler and controlled by a DRX400 console. An automated experiment was obtained using a standard Bruker load experiment, working with Topsipinv 1.3 using ICON-NMR v4.0.7. For non-conventional spectroscopy, data were obtained via Topspin alone. Data are reported in ppm () as follows: chemical shifts (multiplicity, integration, coupling constant (Hz)).

In that¹³In C solid state NMR, the peak position may vary depending on factors such as signal-to-noise ratio, peak width, temperature, rotational speed, decoupling efficiency, magic angle settings, data processing operations and parameters, and software peak extraction algorithms. Furthermore, the peak positions are related to the chemical shift reference operation. Several different chemical shift reference standards may be used and will not necessarily produce the same results. The use of different chemical shift reference standards can produce peak positions several ppm apart. However, if different reference standards are used, or if the analyst uses different values for the reference peak positions of the same standard, then typically the positions of all peaks in the same direction will have systematic variations.

In certain embodiments, provided herein¹³The ppm value in C solid state NMR varied to the extent of about. + -. 0.2ppm, but the same peaks were still described.

Differential Scanning Calorimetry (DSC)

DSC data were collected on a Mettler DSC 823E equipped with a 34-bit autosampler. The energy and temperature of the instrument were calibrated using the identified indium. In a pinhole aluminum pan, 0.5-2mg of each sample is heated from 25 ℃ to 300 ℃ usually at 10 ℃/min. A nitrogen purge of 50mL/min is typically maintained over the sample. The STARe v9.20 software was used as instrument control and data analysis software.

Thermogravimetric analysis (TGA)

TGA data was collected on a Mettler TGA/SDTA851e equipped with a 34 bit auto-sampler. The instrument was temperature calibrated using the identified indium. Typically, 3-6mg of each sample is loaded onto a pre-weighed aluminum crucible and heated from ambient temperature to 350 ℃ at 10 ℃/min. A nitrogen purge of 50mL/min was maintained over the sample.

IR spectroscopy

IR data were collected on a Perkin Elmer Spectrum One FT-IR spectrometer with a Universal ATR Sampling Access and a pyroelectric DTGS detector (deuterated triglycine sulfate).

Chiral purity by HPLC

Chiral HPLC analysis was performed on an Agilent HP1100 tandem system equipped with a diode array detector and using ChemStation software vb.02.01-SR1 or SR2 using the methods detailed below:

chiral HPLC method parameters for the analysis of 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester

Sample preparation	1.0mg/mL，DCM
		Column	Chiralpak IC,250x 4.6mm
Column temperature (. degree. C.)	35
		Injection (L)	10
And (3) detection: wavelength, Bandwidth (nm)	235,4
		Flow rate (mL/min)	1.0
Phase A	20%/80% EtOH/Hexane
		Phase B	N/A

Synthetic examples

Example 1: salt screening of intermediate (A)

The co-former supplied or prepared in salt form in table 1 was eluted on an ion exchange resin to isolate its free acid counterpart. However, due to the chemical instability of the free acid, the co-former containing sulfuric acid is not directly used as the free acid. Instead, the co-former containing sulfuric acid is dissolved in a suitable solvent in the form of a salt and one molar equivalent of HCl (4N HCl/dioxane) is added for each sulfuric acid group. The co-formers Ac20, Ac125, and Ac69 were added as free acid solids. The co-formers Ac38, Ac49, Ac111, Ac18, and Ac115 were added as solutions of free acid in ethanol at concentrations of 5M, 1M, 5M, and 5M, respectively. The following coformers were added as a solution of the free acid in aqueous ethanol: ac70 (10% v/v,0.45M), Ac75 (10% v/v,0.45M), Ac126 (25% v/v,0.8M), Ac4 (monohydrate, 7% v/v,1M), Ac117 (20% v/v,0.4M), Ac116 (10% v/v,0.45M), and Ac127 (35% v/v, 0.5M). The following coformers were added as sodium salt solutions (except for one molar equivalent of 4N HCl/dioxane): ac118(0.8M in ethanol), Ac110(5M in ethanol), Ac113(3.7M in THF), Ac114(0.8M in 80% by volume aqueous THF), and Ac119(1.3M in 25% by volume aqueous THF). The co-former Ac120 was added as a 0.5M solution of the free acid in water. The following co-formers were added as ammonium salts in solution (except for one molar equivalent of 4 NHCl/dioxane): ac121 (diammonium salt, 0.7M in 38% by volume aqueous THF), Ac122(1.4M in water), Ac112(0.5M in water), Ac123(1M in 50% aqueous THF), and Ac124(1.3M in water).

TABLE 1 Coformers

A clear solution of intermediate (a) (30 or 50mg) in ethanol (20 vol), MEK (40 vol) and MIBK (20 vol) was prepared at 50 ℃. Coformic acid (1.2mol equivalent) prepared as described previously was added and slurried for about 1-2 hours at 50 ℃. The suspension was cooled to room temperature and slurried at room temperature for 2 days. The solution was then cooled to 5 ℃ and 20 ℃ and slowly evaporated. The gum was subjected to maturation cycles (temperature cycling).

TABLE 2 trial conditions to obtain a co-former salt of crystalline compound (1) (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester

Scheme 1 below describes the use of Ac49 as a co-former acid for the preparation of compound (1a) and for chiral resolution of compound (1).

Scheme 1

Example 2 preparation of Compound (1) Using scheme 1

Step 1a

Intermediate (A) (5g,12.5mmol) was dissolved in 9:1v/v MIBK/ethanol (70mL,14 volumes) with stirring at 50 ℃ and dissolution was observed in less than about 5 minutes. [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid monohydrate (4.1g,12.5mmol) was added and dissolution was observed over about 10-20 minutes. Compound (1a) (95% e.e.,5mg, 0.1% w.) was then seeded and the system equilibrated at 50 ℃ for about 1 hour, cooled at 0.15 ℃/min to about 20 ℃, and then equilibrated at 20 ℃ for 2 hours. The solid phase was isolated by filtration, washed with ethanol and dried at about 50 ℃ and 3mbar for about 2 to 3 hours to give compound (1a) as 0.6 molar equivalent of EtOH solvate and 0.6 molar equivalent of hydrate (93.4% e.e.).

Step 1b

Compound (1a) was then suspended at 95/5 vol% in MIBK/ethanol (38mL,10 vol) at 50 ℃ with stirring. After holding at 50 ℃ for about 2 hours, the suspension was cooled to about 5 ℃ and held for 10 to 15 hours. The solid phase is recovered by filtration and dried at about 50 ℃ and 3mbar for about 3 hours. Compound (1a) (97.4% e.e.).

Step 2

Compound (1) was liberated by suspending compound (1a) (3.9g,5.5mmol) in 20mL of water at room temperature and treating with 5M sodium hydroxide/water (1.3mL,1.2mol) without optional reslurry of step 1. The mixture is kept at room temperature for about 15 hours and the solid is isolated by filtration and dried at 50 ℃ and 3mbar for about 3 hours. Compound (1) was recovered (94.4% e.e.).

Example 3 Large Scale preparation of Compound (1) Using scheme 1

The procedure of example 1 was carried out using 3.3kg of intermediate (a) and respective solvent ratios, yielding 95.7% e.e. (step 1 a); 99.2% e.e. (step 1 b); and 99.2% e.e. (step 2).

Example 4 alternative preparation of Compound (1) Using scheme 1

Step 1a

Intermediate (A) (751mg,1.86mmol)) was dissolved in 9:1v/v MIBK/ethanol (7.5mL,10 volumes) with stirring at 50 ℃. Adding [ (1S) -inner]- (+) -3-bromo-10-camphorsulfonic acid monohydrate (620mg,1.88mmol,1 equiv.). Precipitate formation was observed at 50 ℃ for about 1 hour. The system was then cooled at 0.1 deg.C/min to about 5 deg.C and then equilibrated at 5 deg.C for about 60 hours. The solid phase was isolated by filtration and dried at about 50 ℃ and 3mbar for about 2 hours to give compound (1a) (92% e.e.). Referring to FIGS. 1-4, XRPD (FIG. 1), chiral HPLC (FIG. 2),¹h NMR (fig. 3) and TGA/DSC analysis (fig. 4). The XRPD pattern of the material from example 3 was similar to that of example 1, with only a slight shift in the position of the specific diffraction peak (highlighted by black arrows in fig. 1).¹H NMR was consistent with a single salt of compound (1a) containing 0.5 molar equivalents of EtOH and 0.6 wt% residual MIBK. TGA analysis showed that a gradual mass loss of 3.5% (possibly representing a loss of 0.5 molar equivalents of EtOH) occurred between 25 and 90 ℃ and a gradual mass loss of 1.2% (possibly representing a loss of adsorbed water) occurred between 90 ℃ and 160 ℃. DSC analysis results with a broad endotherm indicating desolvation between 25 ℃ and 90 ℃ and an endotherm indicating melting/degradation at 135 ℃.

Step 1b

Compound (1a) (100.3mg,0.141mmol) was resuspended at 95:5v/vMIBK/EtOH (1mL,10 volumes) and stirred for 1 hour at 50 ℃ before being cooled to 5 ℃ at 0.1 ℃/min. After being held at 5 ℃ overnight, the solid (99.4% e.e.) was recovered by filtration. No further shifts of the XRPD diffraction peaks were detected (fig. 5; compare fig. 1). FIG. 6 shows chiral HPLC of compound (1 a).

Step 2

Compound (1a) of step 1a (100.2mg,0.141mmol) was suspended in water (2mL,20 volumes) at 50 ℃ and 5M NaOH/water (34 μ L,1.2 molar equivalents) was added. The resulting suspension was kept overnight at 50 ℃, cooled to room temperature (uncontrolled cooling) and filtered to give compound (1) (92% e.e.). Chiral purity was not affected by this step and [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid was not detected by NMR. Figure 7 compares the XRPD of compound (1) of step 2 with the starting material intermediate (a) of step 1. FIG. 8 shows NMR of compound (1) of step 2 and starting material intermediate (A) of step 1.

Example 5 alternative preparation of Compound (1) Using scheme 1

Step 1a

Intermediate (a) (1 eq) was added to a solution of MIBK (12-13 vol), ethanol (1-1.5 vol) and water (0.05-0.10 vol) with stirring and the reaction mixture was heated to an internal temperature of about 48 ℃ to about 52 ℃ over 15 minutes. Adding [ (1S) -inner]- (+) -3-bromo-10-camphorsulfonic acid (1 equivalent) and the reaction mixture is stirred at an internal temperature of about 48 ℃ to about 52 ℃ for about 5-10 minutes until dissolution occurs. Seed crystals of compound (1a) were added and the reaction was allowed to proceed at an internal temperature of about 48 ℃ to about 52 ℃ for 1 hour. The reaction mixture was cooled to about 19-21 ℃ at a rate of 0.15 ℃/min. The suspension was stirred at an internal temperature of about 19 ℃ to 21 ℃ for 2 hours, then collected by filtration and washed twice with ethanol. Passing the product through¹HNMR and¹³c NMR (fig. 13a and 13b), IR spectrum (fig. 14), DSC (fig. 15) and chiral HPLC (fig. 16).

Step 2a

To compound (1a) (1 equivalent) was added acetone (1.1 vol), IPA (0.55 vol), and methanol (0.55 vol), and the reaction mixture was heated to an internal temperature of about 38 ℃ to 42 ℃. Aqueous ammonia (25%) (1.3 equivalents) was added and the reaction mixture was stirred for about 10 minutes. The reaction mixture was confirmed to have a pH of 7 or more, and the next step was carried out. Water (0.55 vol) was added, the reaction mixture was cooled to an internal temperature of about 35 ℃, seed crystals of compound (1) were added, and the reaction mixture was stirred for about 10 minutes. Water (3.3 volumes) was added dropwise over about 30 minutes, the suspension was cooled to an internal temperature of about 0 ℃ to 5 ℃ over 30 minutes, and the reaction mixture was stirred for 15 minutes. The solid was collected by filtration and washed three times with water.

Step 2b

To the product of step 2a) was added acetone (4 vol), IPA (1 vol) and methanol (1 vol) and the reaction mixture was heated to an internal temperature of about 38 ℃ to 42 ℃ to give a clear solution. Water (2 volumes) and seed crystals of compound (1) were added and the system was stirred at an internal temperature of about 35 ℃ for about 15 minutes. Water (342mL) was added dropwise over about 30 minutes. The suspension was then cooled to an internal temperature of about 0 ℃ to 5 ℃ over 30min and stirred for an additional 15 minutes. The solid was collected by filtration, washed twice with water, and the chiral purity was determined. If 99% e.e., the solid is dried under reduced pressure at an internal temperature of about 60 ℃ to give compound (1). Product passing¹H NMR (FIG. 19),¹³C NMR (fig. 20), IR (fig. 21), DSC (fig. 22), chiral HPLC (fig. 23).

Scheme 2 below describes the use of Ac110 as the co-former acid for the preparation of compound (1b) and for chiral resolution of compound (1).

Scheme 2

Example 6 preparation of Compound (1) Using scheme 2

Step 1a

Intermediate (a) (102mg,0.256mmol) was dissolved in MIBK (1mL,10 volumes) at 65 ℃ with stirring. A suspension was observed after adding a solution of (1S) -phenylethanesulfonic acid in MIBK (3.8M,80 μ L,1 molar equivalent) prepared using procedures known to those skilled in the art and holding at 65 ℃ for 30 minutes. The system was held at 65 ℃ for an additional 30 minutes before cooling to 5 ℃ at 0.1 ℃/min. After a overnight hold at 5 ℃, the solid was filtered and dried at 50 ℃ for about 2 hours at a pressure of 3mbar to give compound (1 b). See XRPD of FIGS. 9-12 (FIG. 9)) Chiral HPLC (FIG. 10),¹H NMR (fig. 11) and TGA/DSC analysis (fig. 12a and 12 b). The XRPD pattern of the solid obtained in example 5 is different from the XRPD pattern obtained with the solid from the salt screen of example 1, but consistent with the production of different solids in examples 1 and 5.¹H NMR was consistent with the single salt with 0.3 wt% dioxane residue. In fig. 12a, the thermal behavior is consistent with the unsolvated form showing melting/degradation at 201 ℃. FIG. 12b compares the melting patterns of compound (1b) in example 5 and compound (1b) in example 1.

Steps 1b and 2 can be performed using similar procedures as used in examples 2-5.

EXAMPLE 7 polymorphism of Compound (1a)

Compound (1) (92% e.e.,10mg, mmol) was placed in a 1.5mL vial and the solvent of table 3(1 mL or less) was added at 50 ℃ until dissolution was achieved. Adding solid [ (1S) -in at 50 DEG C]- (+) -3-bromo-10-camphorsulfonic acid. The sample was held at 50 ℃ for about 1 hour, after which it was cooled to room temperature overnight (uncontrolled cooling rate). The clear solution was cooled to 4 deg.C, then to-20 deg.C and evaporated at room temperature. Any gum obtained after evaporation was resuspended in diethyl ether. The resulting solid phase was passed by XRPD and (if relevant) by¹H NMR and TGA/DSC.

TABLE 3 polymorphism Condition of Compound (1a)

C.s. means clear solution and susp. means suspension. By "a" is meant that the XRPD diffractogram is new but similar to that of Ac49 of example 1. "B" means that the XRPD diffraction pattern is the same as that of Ac49 of example 1. "m.e." means molar equivalents.

Each of the seven solvents in which solvates (excluding heterosolvates) were observed was mixed with MIBK (90% by volume). A solution of intermediate (a) was prepared in a solvent mixture (10 volumes) at 50 ℃ and [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid (1 molar equivalent) was added. The resulting clear solution was cooled to 5 ℃ at 0.2 ℃/min. Surprisingly, no crystallization was reported in any of the samples. Seeding with several crystals of each solvate was performed at about 25 ℃. The solid phase was analyzed by XRPD and the liquid phase by chiral HPLC. See table 4 for a summary of results (where "Dias 2" is the (2R,3R) diastereomer of compound (1 a)).

TABLE 4 solvate analysis of Compound (1a)

As seen in table 4 above, the ethanol/MIBK system yielded compound (1a) in 93% purity, which indicates that compound (1a) does crystallize in very pure form as an ethanolate solvate.

Other objects, features, and advantages of the compounds, methods, and compositions described herein will become apparent from the following description. It should be understood, however, that the description and specific examples, while indicating specific implementations, are given by way of illustration only, since various changes and modifications within the spirit and scope of the description of the invention will become apparent from this detailed description.

All publications, including patents, patent applications, and published patent applications, cited in this application are hereby incorporated by reference for all purposes.

Claims (19)

1. A co-adult salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate thereof and additionally optionally in the form of a hydrate thereof.
2. 2. The coformer salt of claim 1, wherein the coformer salt is in a substantially pure crystalline form.
3. 3. The coformer salt of claim 1 or 2, wherein the coformer salt is the [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonic acid salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.
4. 4. The conformer salt of any one of claims 1 to 3, wherein the conformer salt is in a crystalline form exhibiting at least one of:

   solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum;

   a differential scanning calorimetry thermogram having a broad endotherm between 25 ℃ and 90 ℃ and an endotherm with a maximum between about 135 ℃ and 147 ℃;

   thermogravimetric thermograms indicated as solvated species; or

   X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5 and 22.
5. 5. The conformer salt of any one of claims 1 to 3, wherein the conformer salt is in a crystalline form exhibiting at least one of:

   solid state with peaks at 210.3, 25.3, 21.8, 20.8, 19.5 and 18.5ppm + -0.2 ppm¹³C NMR spectrum; or

   X-ray powder diffraction pattern comprising peaks at 2 theta angles ± 0.22 theta angles of 6.7, 9.7, 18.5, 19.5 and 22.
6. 6. The coformer salt of claim 1 or 2, wherein the coformer salt is (S) -1-phenylethanesulfonate salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.
7. 7. A method of preparing a co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate comprising:

   (1) treating methyl 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate with a co-former at elevated temperature in one or more of the solvents of step 1a) to form a solution of step 1 a);

   wherein the one or more step 1a) solvents are selected from C_1-6Ketones, C_1-6Alcohols, ethyl acetate, tetrahydrofuran, toluene, acetonitrile, heptane, dioxane, and water;

   (2) allowing the step 1a) solution to stand under conditions sufficient for the coformer salt to precipitate out in solid form; and

   (3) isolating the co-former salt solid form.
8. 8. The method of claim 7, wherein the coformer salt is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate and the one or more step 1a) solvents are selected from the group consisting of acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol, isopropanol, and butanol.
9. 9. The method of claim 7 or 8 wherein the coformer salt is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate and the step 1a) solvent is methyl isobutyl ketone, water and ethanol.
10. 10. The method of claim 7 or 8, wherein the coformer salt is [ (1S) -endo ] - (+) -3-bromo-10-camphorsulfonate and the step 1a) solvent is methyl isobutyl ketone and ethanol.
11. 11. The method of any one of claims 7-10, further comprising recrystallizing or reslurrying the coformer salt in one or more of the step 1b) solvents.
12. 12. The method of any one of claims 7-11, wherein the co-former salt of methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate is in a crystalline form.
13. 13. The method of any one of claims 7-12, further comprising:

    (4) suspending a co-former salt of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester in one or more of the solvents of step 2a) at room temperature or elevated temperature to form a solution of step 2a) and dissolving the co-former salt in a solvent selected from NaOH, NH, or a mixture thereof₃Aqueous solution, NaCO₃NaOAc or NaHCO₃Treating the step 2a) solution with a base;

    wherein the solvent of step 2a) is selected from C_1-6Ketones, C_1-6Alcohol and water;

    (5) allowing the step 2a) solution to stand under conditions sufficient to precipitate out a solid form of the coformer salt; and

    (6) isolating said (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester as a solid.
14. 14. The process of any one of claims 7-13, wherein the step 2a) solvent is selected from acetone, methyl ethyl ketone, methyl isobutyl ketone, methanol, ethanol, propanol or isopropanol; and the base is NH₃An aqueous solution.
15. 15. The process of any of claims 7-14, wherein the step 2a) solvents are acetone, methanol, and 2-propanol; and the base is NH₃An aqueous solution.
16. 16. The process of any of claims 7-14, wherein the step 2a) solvents are acetone, methanol, and isopropanol; and the base is NH₃An aqueous solution.
17. 17. The method of any one of claims 7-16, further comprising recrystallizing or reslurrying the coformer salt in one or more of the step 2b) solvents.
18. 18. The process of any one of claims 7-17, wherein (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester is in crystalline form.
19. 19. The compound (2S,3S) -methyl 7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate, optionally in the form of a solvate and additionally optionally in the form of a hydrate, prepared by: treating the co-former salt of (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylic acid methyl ester with a base and isolating the methyl (2S,3S) -7-fluoro-2- (4-fluorophenyl) -3- (1-methyl-1H-1, 2, 4-triazol-5-yl) -4-oxo-1, 2,3, 4-tetrahydroquinoline-5-carboxylate.